Effect of Orlistat, a Novel Anti-Obesity Agent, on the Pharmacokinetics and Pharmacodynamics of Pravastatin in Patients with Mild Hypercholesterolaemia

Author： Oo C.Y.   Akbari B.   Lee S.   Nichols G.   Hellmann C.P.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.17, Iss.3, 1999-03, pp. : 217-223

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Orlistat: its current status as an anti-obesity drug

By Ballinger A.   Peikin S.R.  

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 109-117

Elsevier

Access to resources Recommend Favorite

Novel anti-obesity drugs

By Proietto J.   Fam B.C.   Ainslie D.A.   Thorburn A.W.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1317-1326

Informa Healthcare

Access to resources Recommend Favorite

Steady-State Pharmacokinetics of Pravastatin in Children with Familial Hypercholesterolaemia

By Wiersma H.E.   Wiegman A.  

Clinical Drug Investigation, Vol. 24, Iss. 2, 2004-01 ,pp. : 113-120

Adis International

Access to resources Recommend Favorite

α-Lipoic acid, an anti-obesity agent?

By Doggrell Sheila A  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 12, 2004-12 ,pp. : 1641-1643

Informa Healthcare

Access to resources Recommend Favorite

Anti-obesity effect of MPV-1743 AIII, a novel imidazoline derivative, in genetic obesity

By Savontaus E.   Raasmaja A.   Rouru J.   Koulu M.   Pesonen U.   Virtanen R.   Savola J.-M.   Huupponen R.  

European Journal of Pharmacology, Vol. 328, Iss. 2, 1997-09 ,pp. : 207-215

Elsevier

Access to resources Recommend Favorite